Xeris Biopharma (NASDAQ:XERS) Trading Up 8.4% on Insider Buying Activity

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report)'s stock price traded up 8.4% during trading on Tuesday after an insider bought additional shares in the company. The company traded as high as $4.70 and last traded at $4.77. 437,729 shares were traded during mid-day trading, a decline of 78% from the average session volume of 1,978,886 shares. The stock had previously closed at $4.40.

Specifically, insider Kevin Mcculloch purchased 25,000 shares of the company's stock in a transaction that occurred on Friday, June 13th. The stock was purchased at an average cost of $4.38 per share, for a total transaction of $109,500.00. Following the completion of the transaction, the insider now owns 1,708,585 shares of the company's stock, valued at $7,483,602.30. This trade represents a 1.48% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Wall Street Zen lowered Xeris Biopharma from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Craig Hallum boosted their price target on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research report on Friday, March 7th. Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. HC Wainwright reissued a "buy" rating and issued a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Finally, Leerink Partners boosted their target price on Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $6.25.

Xeris Biopharma Stock Performance

The company has a market capitalization of $737.36 million, a price-to-earnings ratio of -10.48 and a beta of 0.71. The firm has a 50-day simple moving average of $4.55 and a two-hundred day simple moving average of $4.14.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to analysts' expectations of $57.61 million. As a group, equities analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. R Squared Ltd raised its holdings in shares of Xeris Biopharma by 27.7% in the 1st quarter. R Squared Ltd now owns 15,730 shares of the company's stock valued at $86,000 after purchasing an additional 3,410 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Xeris Biopharma by 4.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company's stock valued at $273,000 after buying an additional 3,447 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in Xeris Biopharma by 31.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company's stock valued at $55,000 after buying an additional 3,847 shares in the last quarter. Apollon Wealth Management LLC lifted its holdings in Xeris Biopharma by 19.8% during the 1st quarter. Apollon Wealth Management LLC now owns 24,160 shares of the company's stock worth $133,000 after buying an additional 4,000 shares during the last quarter. Finally, Prudential Financial Inc. boosted its position in shares of Xeris Biopharma by 23.4% during the 4th quarter. Prudential Financial Inc. now owns 36,945 shares of the company's stock worth $125,000 after acquiring an additional 7,000 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.